Arbutus Biopharma announced new data from its IM-PROVE I Phase 2a clinical trial, revealing a 50% functional cure rate in a specific patient subset. This rate was observed in HBeAg-negative patients with baseline HBsAg levels less than 1000 IU/mL in Cohort A1, representing 3 out of 6 patients.
The overall functional cure rate in Cohort A1 was 25%, or 3 out of 12 patients. This was achieved with six doses of imdusiran, 24 weeks of pegylated interferon alfa-2α (IFN), and ongoing nucleos(t)ide analogue (NA) therapy.
These data were presented as a late-breaker poster presentation on November 18, 2024, at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2024. The regimen was also noted to be generally safe and well-tolerated.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.